A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis

Part of paid clinical trials in Waltham, Massachusetts.

Sponsor
Bristol-Myers Squibb
Study ID
NCT05744466
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Deucravacitinib — DRUG
    As prescribed by treating clinician
  • Apremilast — DRUG
    As prescribed by treating clinician

Study Details

The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.

Key Dates

Start date
Sep 30, 2022
Status verified
Jul 2024
Primary completion
Dec 10, 2027
Completion
Dec 10, 2027

Study Design

Enrollment
1,500 participants (estimated)

Arms

  • Arm: Cohort 1
    Participants that have initiated deucravacitinib
  • Arm: Cohort 2
    Participants that have initiated apremilast

Primary Outcome Measure

Change in body surface area (BSA) [ Time Frame: At baseline and every 6 months up to 60 months or treatment discontinuation ]

Central Contacts

  • BMS Study Connect Contact Center www.BMSStudyConnect.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain the NCT# and Site #.

Locations (1)

FacilityCityStateZIPSite coordinators
Local InstitutionWalthamMassachusetts02451-

Find similar trials in Waltham, MA

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Local Institution· Waltham, MA

Related Studies